Medunik USA announced Siklos (hydroxyurea), an FDA-approved orphan drug, is now available in 1,000 mg triple-scored tablets to help optimize dosing.
Siklos is the first and only FDA-approved hydroxyurea-based treatment indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients two years of age and older with sickle cell anemia with recurrent moderate to severe painful crises. Siklos has a boxed warning.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
The importance of optimal dosing of hydroxyurea in sickle cell anemia (SCA) patients, based on patient body weight and biological and clinical response, has been well established. This is particularly relevant in pediatric populations, where patient weight is constantly changing.
"Medunik is proud to offer pediatric SCA patients a new option that helps optimize daily dosing. Given that the new triple-scored Siklos 1,000 mg tablets can be divided into four equal parts of 250 mg each, when combined with the 100 mg tablets, it is now possible to adjust dosing in increments as small as 50 mg (starting at a 200 mg dose)," said Dany Hallé, Vice President, Commercial Affairs, at Medunik.